Standardisation of global clinical trial and results databases "desperately needed"
This article was originally published in Scrip
There is a desperate need to standardise the increasingly differing transparency requirements around the world for clinical trials, delegates at the recent Drug Information Association's 22nd Annual EuroMeeting, were told last week.
You may also be interested in...
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.
The EU marketing application for cefiderocol that lost fast track status last July is now up for an opinion by the European Medicines Agency.